In 2008, the Action to Control Cardiovascular Risk in Diabetes trial was halted due to an unexpected number of deaths in the intensive treatment group (aiming for hemoglobin A1c levels less than 6%). Hypoglycemic episodes were thought by some to be a contributing cause, underscoring again the challenge of maintaining tight control while avoiding dangerous excursions into hypoglycemic territory. Albisser and colleagues present a set of articles in this issue of Journal of Diabetes Science and Technology that describe a clinical product developed specifically for this timeless clinical conundrum.
AlbisserAMAlejandroRSperlichMRicordiC. Closing the circle of care with new firmware for diabetes: MyDiaBase+RxChecker. J Diabetes Sci Technol.2009;3 (3): 613–8.
U.S. Department of Health and Human Services: National Heart, Lung, and Blood Institute. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. http://www.nhlbi.nih.gov/health/prof/heart/other/accord/. Accessed March 25, 2009.
